This Article Full Text Full Text (PDF) All Versions of this Article: 109/17/2116    most recent 01.CIR.0000127419.45975.26v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Wadham, C. Articles by Xia, P. Search for Related Content PubMed PubMed Citation Articles by Wadham, C. Articles by Xia, P. Related Collections Pathophysiology Risk Factors Cell signalling/signal transduction Lipid and lipoprotein metabolism Endothelium/vascular type/nitric oxide

(Circulation. 2004;109:2116-2122.)
© 2004 American Heart Association, Inc.

Basic Science Reports

High-Density Lipoproteins Neutralize C-Reactive Protein Proinflammatory Activity

Carol Wadham, PhD; Nathaniel Albanese, BSc; Jane Roberts, BSc; Lijun Wang, BA; Christopher J. Bagley, PhD; Jennifer R. Gamble, PhD; Kerry-Anne Rye, PhD; Philip J. Barter, MD, PhD; Mathew A. Vadas, MBBS, PhD^*; Pu Xia, MD^*

From the Division of Human Immunology, Hanson Institute, Institute of Medical and Veterinary Science (C.W., N.A., J.R., L.W., C.J.B., J.R.G., M.A.V., P.X.), and the University of Adelaide (C.J.B., J.R.G., M.A.V., P.X.), Adelaide, South Australia; and the Lipid Research Group, The Heart Research Institute, Camperdown, NSW (K.-A.R., P.J.B.), Australia.

Correspondence to Pu Xia, MD, Hanson Institute, Frome Road, PO Box 14 Rundle Mall, Adelaide, SA 5000, Australia. E-mail pu.xia{at}imvs.sa.gov.au

Received June 2, 2003; de novo received October 26, 2003; revision received January 13, 2004; accepted January 21, 2004.

Background— C-reactive protein (CRP), a well-recognized marker of atherosclerosis, has recently been suggested to have a direct proinflammatory effect. The constitutive expression of low levels of CRP in normal plasma suggests the likelihood that a natural factor exists to neutralize the effect of CRP. This factor(s) has not yet been identified.

Method and Results— The proinflammatory effect of CRP was measured by the induction of inflammatory adhesion molecules in human umbilical vein endothelial cells (HUVECs). We show that CRP significantly induced upregulation of adhesion molecules in both protein and mRNA levels. The CRP-induced expression of these inflammatory adhesion molecules was completely suppressed when the cells were preincubated with a physiological concentration (1 mg/mL apolipoprotein A-I) of HDLs derived from human plasma (native HDL) or reconstituted HDL (rHDL) at a very low concentration (0.01 mg/mL apolipoprotein A-I). A novel mechanism of HDL inhibition is likely to operate, because (1) rHDL was 100 times more potent than native HDL, (2) preincubation with HDL and its sustained presence were obligatory, and (3) oxidized 1-palmitoyl-2-linoleoyl-sn-glycero-3-phosphocholine was the fundamental active component.

Conclusions— The CRP-induced upregulation of inflammatory adhesion molecules in HUVECs was completely prevented by HDL via their oxidized phospholipid components.

Key Words: lipoproteins • protein • inflammation • atherosclerosis

This article has been cited by other articles:

				I. Kralova Lesna, P. Suchanek, J. Kovar, P. Stavek, and R. Poledne Replacement of dietary saturated FAs by PUFAs in diet and reverse cholesterol transport J. Lipid Res., November 1, 2008; 49(11): 2414 - 2418. [Abstract] [Full Text] [PDF]

				A. J. Murphy, K. J. Woollard, A. Hoang, N. Mukhamedova, R. A. Stirzaker, S. P.A. McCormick, A. T. Remaley, D. Sviridov, and J. Chin-Dusting High-Density Lipoprotein Reduces the Human Monocyte Inflammatory Response Arterioscler Thromb Vasc Biol, November 1, 2008; 28(11): 2071 - 2077. [Abstract] [Full Text] [PDF]

				D J Hausenloy and D M Yellon Targeting residual cardiovascular risk: raising high-density lipoprotein cholesterol levels Postgrad. Med. J., November 1, 2008; 84(997): 590 - 598. [Abstract] [Full Text] [PDF]

				E. M. Hylek, L. Frison, L. E. Henault, and A. Cupples Disparate Stroke Rates on Warfarin Among Contemporaneous Cohorts With Atrial Fibrillation: Potential Insights Into Risk From a Comparative Analysis of SPORTIF III Versus SPORTIF V Stroke, November 1, 2008; 39(11): 3009 - 3014. [Abstract] [Full Text] [PDF]

				D J Hausenloy and D M Yellon Targeting residual cardiovascular risk: raising high-density lipoprotein cholesterol levels Heart, June 1, 2008; 94(6): 706 - 714. [Abstract] [Full Text] [PDF]

				Y. Feng, F. Jacobs, E. Van Craeyveld, C. Brunaud, J. Snoeys, M. Tjwa, S. Van Linthout, and B. De Geest Human ApoA-I Transfer Attenuates Transplant Arteriosclerosis via Enhanced Incorporation of Bone marrow-derived Endothelial Progenitor Cells Arterioscler Thromb Vasc Biol, February 1, 2008; 28(2): 278 - 283. [Abstract] [Full Text] [PDF]

				E. Grad, M. Golomb, I. Mor-Yosef, N. Koroukhov, C. Lotan, E. R. Edelman, and H. D. Danenberg Transgenic expression of human C-reactive protein suppresses endothelial nitric oxide synthase expression and bioactivity after vascular injury Am J Physiol Heart Circ Physiol, July 1, 2007; 293(1): H489 - H495. [Abstract] [Full Text] [PDF]

				B. Zhang, Y. Uehara, S. Hida, S.-i. Miura, D. L. Rainwater, M. Segawa, K. Kumagai, K.-A. Rye, and K. Saku Effects of reconstituted HDL on charge-based LDL subfractions as characterized by capillary isotachophoresis J. Lipid Res., May 1, 2007; 48(5): 1175 - 1189. [Abstract] [Full Text] [PDF]

				R. S. Birjmohun, S. I. van Leuven, J. H.M. Levels, C. van 't Veer, J. A. Kuivenhoven, J. C.M. Meijers, M. Levi, J. J.P. Kastelein, T. van der Poll, and E. S.G. Stroes High-Density Lipoprotein Attenuates Inflammation and Coagulation Response on Endotoxin Challenge in Humans Arterioscler Thromb Vasc Biol, May 1, 2007; 27(5): 1153 - 1158. [Abstract] [Full Text] [PDF]

				C. G. Baums, U. Kaim, M. Fulde, G. Ramachandran, R. Goethe, and P. Valentin-Weigand Identification of a Novel Virulence Determinant with Serum Opacification Activity in Streptococcus suis. Infect. Immun., November 1, 2006; 74(11): 6154 - 6162. [Abstract] [Full Text] [PDF]

				M McMahon, J Grossman, W Chen, and B H Hahn Inflammation and the pathogenesis of atherosclerosis in systemic lupus erythematosus Lupus, November 1, 2006; 15(11_suppl): 59 - 69. [Abstract] [PDF]

				E. Paffen and M. P.M. deMaat C-reactive protein in atherosclerosis: A causal factor? Cardiovasc Res, July 1, 2006; 71(1): 30 - 39. [Abstract] [Full Text] [PDF]

				C. Mineo, H. Deguchi, J. H. Griffin, and P. W. Shaul Endothelial and Antithrombotic Actions of HDL Circ. Res., June 9, 2006; 98(11): 1352 - 1364. [Abstract] [Full Text] [PDF]

				M. Oroszlan, E. Herczenik, S. Rugonfalvi-Kiss, A. Roos, A. J Nauta, M. R Daha, I. Gombos, I. Karadi, L. Romics, Z. Prohaszka, et al. Proinflammatory changes in human umbilical cord vein endothelial cells can be induced neither by native nor by modified CRP Int. Immunol., June 1, 2006; 18(6): 871 - 878. [Abstract] [Full Text] [PDF]

				H. S. Courtney, Y.-M. Zhang, M. W. Frank, and C. O. Rock Serum Opacity Factor, a Streptococcal Virulence Factor That Binds to Apolipoproteins A-I and A-II and Disrupts High Density Lipoprotein Structure J. Biol. Chem., March 3, 2006; 281(9): 5515 - 5521. [Abstract] [Full Text] [PDF]

				P. J. Goldschmidt-Clermont, M. A. Creager, D. W. Lorsordo, G. K.W. Lam, M. Wassef, and V. J. Dzau Atherosclerosis 2005: Recent Discoveries and Novel Hypotheses Circulation, November 22, 2005; 112(21): 3348 - 3353. [Full Text] [PDF]

				P. Barter The role of HDL-cholesterol in preventing atherosclerotic disease Eur. Heart J. Suppl., July 1, 2005; 7(suppl_F): F4 - F8. [Abstract] [Full Text] [PDF]

				J. Chapman Beyond LDL-cholesterol reduction: the way ahead in managing dyslipidaemia Eur. Heart J. Suppl., July 1, 2005; 7(suppl_F): F56 - F62. [Abstract] [Full Text] [PDF]

				K. E. Taylor, J. C. Giddings, and C. W. van den Berg C-Reactive Protein-Induced In Vitro Endothelial Cell Activation Is an Artefact Caused by Azide and Lipopolysaccharide Arterioscler Thromb Vasc Biol, June 1, 2005; 25(6): 1225 - 1230. [Abstract] [Full Text] [PDF]

				H. Tomiyama, Y. Koji, M. Yambe, K. Motobe, K. Shiina, Z. Gulnisa, Y. Yamamoto, and A. Yamashina Elevated C-Reactive Protein Augments Increased Arterial Stiffness in Subjects With the Metabolic Syndrome Hypertension, May 1, 2005; 45(5): 997 - 1003. [Abstract] [Full Text] [PDF]

				S. M. Boekholdt, T. T. Keller, N. J. Wareham, R. Luben, S. A. Bingham, N. E. Day, M. S. Sandhu, J. W. Jukema, J. J.P. Kastelein, C. E. Hack, et al. Serum Levels of Type II Secretory Phospholipase A2 and the Risk of Future Coronary Artery Disease in Apparently Healthy Men and Women: The EPIC-Norfolk Prospective Population Study Arterioscler Thromb Vasc Biol, April 1, 2005; 25(4): 839 - 846. [Abstract] [Full Text] [PDF]

				A. Chait, C. Y. Han, J. F. Oram, and J. W. Heinecke Thematic review series: The Immune System and Atherogenesis. Lipoprotein-associated inflammatory proteins: markers or mediators of cardiovascular disease? J. Lipid Res., March 1, 2005; 46(3): 389 - 403. [Abstract] [Full Text] [PDF]

				P. J. Barter, S. Nicholls, K.-A. Rye, G.M. Anantharamaiah, M. Navab, and A. M. Fogelman Antiinflammatory Properties of HDL Circ. Res., October 15, 2004; 95(8): 764 - 772. [Abstract] [Full Text] [PDF]